Page 21 - Rob Holtackers
P. 21

Introduction | 11

               9.   Kim RJ, Wu E, Rafael A, et al. The use of contrast-enhanced magnetic resonance imaging
                   to identify reversible myocardial dysfunction. N Engl J Med 2000;343(20):1445-1453
               10.  Kim RJ, Fieno DS, Parrish TB, et al. Relationship of MRI delayed contrast enhancement to
                   irreversible  injury,  infarct  age,  and  contractile  function.  Circulation  1999;100(19):1992-
               11.  Simonetti  OP,  Kim  RJ,  Fieno  DS,  et  al.  An  improved  MR  imaging  technique  for  the
                   visualization of myocardial infarction. Radiology 2001;218(1):215-223
               12.  Neilan  TG,  Coelho-Filho  OR,  Danik  SB,  et  al.  CMR  quantification  of  myocardial  scar
                   provides  additive  prognostic  information  in  nonischemic  cardiomyopathy.  JACC
                   Cardiovasc Imaging 2013;6(9):944-954
               13.  Bojer  AS,  Sorensen  MH,  Vejlstrup  N,  et  al.  Distinct  non-ischemic  myocardial  late
                   gadolinium  enhancement  lesions  in  patients  with  type  2  diabetes.  Cardiovasc  Diabetol
               14.  Oakes  RS,  Badger  TJ,  Kholmovski  EG,  et  al.  Detection  and  quantification  of  left  atrial
                   structural remodeling with delayed-enhancement magnetic resonance imaging in patients
                   with atrial fibrillation. Circulation 2009;119(13):1758-1767
               15.  Marrouche NF, Wilber D, Hindricks G, et al. Association of atrial tissue fibrosis identified
                   by delayed enhancement MRI and atrial fibrillation catheter ablation: the DECAAF study.
                   JAMA 2014;311(5):498-506
               16.  Dickfeld T, Kato R, Zviman M, et al. Characterization of radiofrequency ablation lesions
                   with gadolinium-enhanced cardiovascular magnetic resonance imaging. J Am Coll Cardiol
               17.  Akoum N, Wilber D, Hindricks G, et al. MRI assessment of ablation-induced scarring in
                   atrial  fibrillation:  Analysis  from  the  DECAAF  study.  J  Cardiovasc  Electrophysiol
               18.  Fochler  F,  Yamaguchi  T,  Kheirkahan  M,  et  al.  Late  gadolinium  enhancement  magnetic
                   resonance imaging guided treatment of post-atrial fibrillation ablation recurrent arrhythmia.
                   Circ Arrhythm Electrophysiol 2019;12(8):e007174
               19.  Kirstein  B,  Morris  A,  Baher  A,  et  al.  Magnetic  resonance  imaging-guided  cryoballoon
                   ablation for left atrial substrate modification in patients with atrial fibrillation. J Cardiovasc
                   Electrophysiol 2020;31(7):1587-1594
               20.  Kramer CM, Barkhausen J, Bucciarelli-Ducci C, et al. Standardized cardiovascular magnetic
                   resonance imaging (CMR) protocols: 2020 update. J Cardiovasc Magn Reson 2020;22(1):17
               21.  Mahrholdt  H,  Wagner  A,  Judd  RM,  et  al.  Assessment  of  myocardial  viability  by
                   cardiovascular magnetic resonance imaging. Eur Heart J 2002;23(8):602-619
               22.  Kellman P, Arai AE. Cardiac imaging techniques for physicians: late enhancement. J Magn
                   Reson Imaging 2012;36(3):529-542
               23.  Look DC, Locker DR. Time Saving in Measurement of NMR and EPR Relaxation Times. Rev
                   Sci Instrum 1970;41(2):250-251
               24.  Kim RJ, Shah DJ, Judd RM. How we perform delayed enhancement imaging. J Cardiovasc
                   Magn Reson 2003;5(3):505-514
               25.  Setser RM, Chung YC, Weaver JA, et al. Effect of inversion time on delayed-enhancement
                   magnetic  resonance  imaging  with  and  without  phase-sensitive  reconstruction.  J  Magn
                   Reson Imaging 2005;21(5):650-655
               26.  Kellman  P,  Arai  AE,  McVeigh  ER,  et  al.  Phase-sensitive  inversion  recovery  for  detecting
                   myocardial  infarction  using  gadolinium-delayed  hyperenhancement.  Magn  Reson  Med
   16   17   18   19   20   21   22   23   24   25   26